U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Surgisil, LLP - 567886 - 01/23/2020
  1. Warning Letters


Surgisil, LLP MARCS-CMS 567886 —

Delivery Method:
UPS Overnight
Medical Devices

Recipient Name
Peter Raphael, MD
Recipient Title
Chief Executive Officer
Surgisil, LLP

6020 W. Plano Parkway
Plano, TX 75093
United States

Issuing Office:
Office of Medical Devices and Radiological Health, Division III

United States

Dear Dr. Raphael:

The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter dated April 15, 2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Jessica Mu,
Director, Compliance Branch
Office of Medical Devices and
Radiological Health, Division III

Back to Top